196 related articles for article (PubMed ID: 1919901)
21. Immunogenicity and reactogenicity of Haemophilus influenzae type b-meningococcus group B outer membrane protein conjugate vaccine in children 2-60 months of age.
Shehab ZM; Azimi P; Asmar BI; Dunphy MG; Ayoub EM; Dajani AS
Scand J Infect Dis; 1991; 23(6):763-9. PubMed ID: 1815340
[TBL] [Abstract][Full Text] [Related]
22. Disease caused by Haemophilus influenzae type b in the immediate period after homologous immunization: immunologic investigation.
Sood SK; Daum RS
Pediatrics; 1990 Apr; 85(4 Pt 2):698-704. PubMed ID: 2107522
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
[TBL] [Abstract][Full Text] [Related]
24. Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses.
Calandra GB; Lukacs LJ; Jonas LC; Santosham M; Ward JI; Greenberg DP; Daum RS; Matthews H; Vella PP; Ryan JL
Vaccine; 1993; 11 Suppl 1():S58-62. PubMed ID: 8447178
[TBL] [Abstract][Full Text] [Related]
25. Timing of the booster dose with Haemophilus polyribosylribitol phosphate conjugated with Neisseria outer-membrane protein.
Calandra GB; Mendelman PM
J Pediatr; 1992 Jul; 121(1):172. PubMed ID: 1625087
[No Abstract] [Full Text] [Related]
26. Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide--Neisseria meningitidis outer membrane protein.
Ahonkhai VI; Lukacs LJ; Jonas LC; Calandra GB
Vaccine; 1991 Jun; 9 Suppl():S38-41; discussion S42-3. PubMed ID: 1891956
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of Haemophilus influenzae type b polysaccharide-outer membrane protein conjugate vaccine in patients who acquired Haemophilus disease despite previous vaccination with type b polysaccharide vaccine.
Granoff DM; Chacko A; Lottenbach KR; Sheetz KE
J Pediatr; 1989 Jun; 114(6):925-33. PubMed ID: 2786062
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of Haemophilus influenzae type B polysaccharide-diphtheria toxoid conjugate vaccine in adults.
Lepow ML; Samuelson JS; Gordon LK
J Infect Dis; 1984 Sep; 150(3):402-6. PubMed ID: 6332863
[TBL] [Abstract][Full Text] [Related]
29. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB): clinical evaluation.
Ahonkhai VI; Lukacs LJ; Jonas LC; Matthews H; Vella PP; Ellis RW; Staub JM; Dolan KT; Rusk CM; Calandra GB
Pediatrics; 1990 Apr; 85(4 Pt 2):676-81. PubMed ID: 2107518
[TBL] [Abstract][Full Text] [Related]
30. Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland.
Mäkelä PH; Peltola H; Käyhty H; Jousimies H; Pettay O; Ruoslahti E; Sivonen A; Renkonen OV
J Infect Dis; 1977 Aug; 136 Suppl():S43-50. PubMed ID: 408432
[No Abstract] [Full Text] [Related]
31. Immunization of 2-month-old infants with protein-coupled oligosaccharides derived from the capsule of Haemophilus influenzae type b.
Anderson P; Pichichero ME; Insel RA
J Pediatr; 1985 Sep; 107(3):346-51. PubMed ID: 3875705
[TBL] [Abstract][Full Text] [Related]
32. Differing serologic responses to an haemophilus influenzae type b polysaccharide-neisseria meningitidis outer membrane protein conjugate (PRP-OMPC) vaccine in australian aboriginal and caucasian infants - implications for disease epidemiology.
Guthridge S; McIntyre P; Isaacs D; Hanlon M; Patel M
Vaccine; 2000 May; 18(23):2584-91. PubMed ID: 10775792
[TBL] [Abstract][Full Text] [Related]
33. Interim report of a controlled field trial of immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg county, North Carolina (March 1974-March 1976).
Parke JC; Schneerson R; Robbins JB; Schlesselman JJ
J Infect Dis; 1977 Aug; 136 Suppl():S51-6. PubMed ID: 408433
[TBL] [Abstract][Full Text] [Related]
34. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
Jennings HJ
Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
[No Abstract] [Full Text] [Related]
35. Antibody levels achieved in infants by course of Haemophilus influenzae type B polysaccharide/diphtheria toxoid conjugate vaccine.
Eskola J; Käyhty H; Peltola H; Karanko V; Mäkelä PH; Samuelson J; Gordon LK
Lancet; 1985 May; 1(8439):1184-6. PubMed ID: 2860387
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein.
Einhorn MS; Weinberg GA; Anderson EL; Granoff PD; Granoff DM
Lancet; 1986 Aug; 2(8502):299-302. PubMed ID: 2874327
[TBL] [Abstract][Full Text] [Related]
37. Haemophilus influenzae type b polysaccharide vaccines.
Granoff DM; Cates KL
J Pediatr; 1985 Sep; 107(3):330-6. PubMed ID: 3897497
[No Abstract] [Full Text] [Related]
38. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB).
Vella PP; Staub JM; Armstrong J; Dolan KT; Rusk CM; Szymanski S; Greer WE; Marburg S; Kniskern PJ; Schofield TL
Pediatrics; 1990 Apr; 85(4 Pt 2):668-75. PubMed ID: 2107517
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine formulation in healthy adults.
Bulkow LR; McMahon BJ; Wainwright RB; Parkinson AJ; Wainwright KY; House J
Arctic Med Res; 1993 Jul; 52(3):118-26. PubMed ID: 8397580
[TBL] [Abstract][Full Text] [Related]
40. Immunologic considerations for the development of conjugate vaccines.
Garner CV; Pier GB
Contrib Microbiol Immunol; 1989; 10():11-7. PubMed ID: 2510971
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
